Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)- resistant human ovarian cancer cell line AG6000 to standard and investigational drugs
A. M. Bergman, G. Giaccone, C. J A Van Moorsel, R. Mauritz, P. Noordhuis, H. M. Pinedo, G. J. Peters
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)- resistant human ovarian cancer cell line AG6000 to standard and investigational drugs'. Together they form a unique fingerprint.